The use of erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin in preterm and term infants has been studied for over 20 years. Recent investigations have explored the potential neuroprotective effects of ESAs. We review the recent clinical trials and experimental animal models that provide evidence in support of using ESA to improve the neurodevelopmental outcomes in term and preterm infants.
INTRODUCTION
Prematurity is a significant risk factor for neurodevelopmental impairment. Associated long-term neurodevelopmental deficits, such as mental retardation, cerebral palsy, and learning disabilities, are common morbidities in former premature infants [1] . Although significant progress has been made in improving the survival of extremely low birth weight (ELBW) infants, improved neurodevelopmental outcomes have not been attained. Specific targeted neuroprotective strategies are necessary and erythropoietin (Epo) is a promising neuroprotective agent, supported by both animal and human studies. This review outlines the basic science data that supports Epo as a neuroprotective agent, with a specific focus on its role in preserving white matter development. Clinical studies that demonstrate efficacy in both premature infants and in term infants with a history of hypoxic-ischemic encephalopathy (HIE) will be reviewed.
POTENTIAL NEUROPROTECTIVE MECHANISMS OF ERYTHROPOIETIN
Multiple animal studies have demonstrated significant neuroprotective effects of Epo administration, both in term and preterm models. Although Epo likely mediates many processes important to normal brain development, its effects on oligodendrogenesis and white-matter formation are of specific interest because of premature birth associated white matter injury [2] . The Epo receptor (EpoR) is expressed throughout all stages of oligodendrocyte development; however, receptor expression is significantly increased following injury [3] [4] [5] [6] . As such, Epo is accepted as an important regulator of normal oligodendrocyte differentiation and development, and is integral to white-matter neuroprotection in the preterm infant. Although the exact cellular mechanisms underlying the neuroprotective effects of Epo are not completely delineated, many studies have identified potential mechanisms of action, including improved oligodendrocyte maturation leading to white matter preservation, decreased apoptosis, anti-inflammatory effects, and antioxidant/antiexcitatory properties.
In the brain, Epo synthesis is regulated by several mechanisms, including hypoxia-induced activation of hypoxia-inducible factor 1 (HIF-1), insulin, hypoglycemia, and excitatory neuronal activity [7] [8] [9] . In addition, EpoR expression is upregulated in neurons by proinflammatory cytokines in response to tissue injury [10] . Signaling via the EpoR pathway inhibits apoptosis, minimizes excitatory damage through downregulation of glutamate release, and reduces the production of proinflammatory cytokines [11] [12] [13] [14] . Epo itself may be anti-inflammatory, though some speculate that inflammation is decreased secondary to an Epo-mediated reduction in apoptosis [15, 16] . In addition, Epo restricts vascular permeability across the blood-brain barrier by activating EpoR-dependent intracellular signaling pathways [17] . Whereas prior studies have focused on the effects of Epo on neurons and astrocytes, more recent studies have investigated the specific neuroprotective effects on developing oligodendrocytes.
OLIGODENDROCYTE DIFFERENTIATION AND SURVIVAL
Oligodendrocytes are generated in waves during the perinatal period and their development is tightly regulated by cell-intrinsic processes as well as the extracellular environment [18] . Any disruption in this environment renders the developing oligodendrocyte vulnerable to potential maldevelopment and thus compromises subsequent white matter formation [19, 20] Fig. 1 . Oligodendrocyte progenitor cells (OPCs) express EpoR, and receptor expression is upregulated following perinatal brain injury [6] . Signaling via EpoR is an important trophic factor during embryonic and fetal brain development, but is not structurally critical [4, [21] [22] [23] . In addition, multiple in-vitro studies reveal that in times of stress, neural cells overexpress EpoR, and in the absence of Epo ligand, these cells subsequently undergo apoptosis [24, 25] . Such studies highlight an important neuroprotective role for Epo following injury and during early postnatal neurodevelopment; and have led to significant interest in how Epo may impart oligodendrocyte specific neuroprotection. In support of this, several recent animal models of perinatal brain injury have demonstrated improved myelin basic protein expression after systemic Epo administration [26 && ,27-31] .
POSTNATAL OLIGODENDROGENESIS
The subventricular zone is an accepted primary source of postnatal neurogenesis and is also an important source of astrocytes and oligodendrocytes during early neurodevelopment [32] . A recent study of neonatal stroke in the rat model demonstrated that exogenous Epo administration improved oligodendrogenesis and resulted in less apoptosis in injured striatum following injury. Mechanisms underlying these changes included increased progenitor proliferation, decreased cell death, and a cellular fate switch [33 && ].
ANTIAPOPTOTIC EFFECTS ON DEVELOPING WHITE MATTER
The antiapoptotic effects of Epo are well described in erythropoietic cells and are likely similar in neural cells. Multiple pathways have been evaluated in the central nervous system (CNS) and evidence of specific antiapoptotic mechanisms vary according to CNS cell type. Epo is a known regulator of the Bcl-2 family of antiapoptotic genes and shifts the Bcl-2/Bax ratio toward cell survival in microglia [34, 35] .
Another potential antiapoptotic effect of Epo in microglia is via mediation of poly(ADP-ribose) polymerase inhibitors (PARP-1) [29] . PARP-1 functions in DNA replication, transcription, and repair; and is activated by DNA damage [36, 37] . Whereas PARP-1 may promote cell repair, its overactivation contributes to cell death. Overactivation of PARP-1 mediates microglial activation in CNS injury and can be inhibited by Epo administration, thus decreasing microglial-induced neonatal white matter injury [29] . Alternatively, effects may occur in developing oligodendrocytes, thus supporting oligodendrocyte maturation. In a perinatal white matter injury model of embryonically induced, transient systemic hypoxiaischemia, rat pups treated with Epo demonstrated a significant reduction in cleaved caspase-3 expression at postnatal days 5 and 9 in the white matter [6] , demonstrating a protective effect of oligodendrocytes themselves.
KEY POINTS
Recent clinical studies demonstrate evidence for significantly improved neurodevelopmental outcomes in neonates treated with ESAs, following extreme prematurity and perinatal brain injury.
Basic science studies demonstrate that ESAs prevent the apoptosis of developing oligodendrocytes and concomitantly support oligodendrocyte survival and maturation following injury.
ESAs appear to specifically support oligodendrogenesis.
OLIGODENDROCYTE DEVELOPMENT AND MATURATION
In cell culture studies examining the effects of Epo administration on embryonic rat oligodendrocytes, Epo increased myelin basic protein expression and promoted oligodendrocyte process formation. These findings suggest that Epo mediates oligodendrocyte maturation during early postnatal development [38] . Similar mechanisms were recently demonstrated in an in-vitro model of prenatal transient systemic hypoxia-ischemia. In this study, cells exposed to hypoxic-ischemic injury and glutamate excitotoxicity demonstrated a marked benefit from Epo administration [26 && ]. This finding further delineates the potential importance of exogenous Epo administration to extremely premature infants, who not only have underdeveloped white matter, but also are exposed to multiple insults during a critical period of neurodevelopment.
CLINICAL STUDIES
Both retrospective studies and prospective randomized trials have been performed in neonatal populations at greatest risk for long-term developmental abnormalities, namely extremely low birth weight infants, and term infants with HIE. Darbe and Epo recipients also scored significantly higher on a test for object permanence (P ¼ 0.05). No infants in the ESA group had cerebral palsy, compared with five in the placebo group (P < 0.001). No differences among groups were found in visual or hearing impairment, and overall neurodevelopmental impairment was significantly lower in the ESA group compared with placebo (odds ratio 0.18; 95% confidence interval 0.05-0.63). This is the first study to report improved developmental outcomes in preterm infants receiving Darbe. If confirmed by a larger trial, Darbe might be more advantageous given its weekly dosing schedule. Similar to previous large randomized trials, we saw no differences in the incidence of any stage of retinopathy of prematurity (ROP) during the hospital phase, and no differences in visual impairment at 18-22 months corrected age. Meta-analyses first published in 2006 suggested an association between early (first week of life) Epo administration and ROP greater than stage 2 [44] compared with late Epo administration [45] . Revised meta-analyses corrected a previous misclassification of a single-center Epo study into the late Epo administration group. Close ophthalmologic evaluation for ROP continues to be a priority in clinical trials in preterm infants.
A high-dose Epo study is in progress in Switzerland (NCT00413946). Leuchter et al. [46] randomized 420 infants during the first three hours of life to receive EPO (3000 U/kg body weight) or placebo intravenously at 3, 12-18, and 36-42 h after birth. Enrollment is complete, and developmental followup is in progress. There were no differences in IVH or ROP in a preliminary report of the first 100 randomized infants.
ERYTHROPOIESIS-STIMULATING AGENTS STUDIES IN TERM INFANTS
Two studies evaluating Epo for neuroprotection in term infants with HIE have been published since the previous review [13] . The first study, by Elmahdy et al. [47] from Egypt, examined the biochemical and neurophysiologic parameters associated with Epo administration, 2500 units/kg subcutaneously for 5 days (NCT00945789). In total, 30 infants with mild-to-moderate HIE were randomized to Epo or control. An additional 15 term infants were included as healthy controls. Serum nitric oxide was measured at enrollment for all 45 infants and after 2 weeks for the HIE infants. EEGs were performed at enrollment and at 2-3 weeks; MRIs were performed at 3 weeks, and neurologic evaluations were performed at 6 months.
Serum nitric oxide levels were elevated in the infants with HIE, compared with healthy controls. Infants with HIE who received Epo had improvement in EEG findings and nitric oxide levels. MRIs were not different between the HIE infants, but Epo recipients had fewer neurologic and developmental abnormalities at 6 months. The authors concluded that Epo administration to infants with HIE to protect against encephalopathy was feasible.
The key issue with this study is that none of the infants were cooled. Current standard of care in the USA is to provide hypothermia for infants with moderate-to-severe HIE. In an effort to evaluate the safety, efficacy, and pharmacokinetics of Epo given in conjunction with hypothermia, Wu et al. [48 && ] randomized 24 infants with moderate-tosevere HIE to an open-label, dose-escalation trial of Epo [Neonatal Erythropoietin in Asphyxiated Term Newborns (NEAT) Trial, NCT00719407]. Infants received one of four doses of Epo (250, 500, 1000, or 2500 units/kg) administered intravenously every other day for up to six doses. Pharmacokinetics was performed with the first, second, and last doses, and infants were monitored closely for any adverse effects.
Epo followed nonlinear pharmacokinetics, but did not accumulate with multiple dosing. The area under the curve was 50 306, 131 054, and 328 002 unit Â h/l for 500, 1000, and 2500 units/kg, respectively. No serious adverse effects or deaths were reported. They concluded that 1000 units/kg Epo administered intravenously in conjunction with hypothermia was well tolerated and produced plasma concentrations that in previous studies were neuroprotective in animals.
On the basis of the previous studies, a number of multicenter clinical trials evaluating Epo in conjunction with hypothermia in term infants with HIE are being planned. Only one study to date has evaluated Darbepoetin as a potential neuroprotective agent in term infants undergoing hypothermia as treatment for HIE. ] evaluated the effects of Darbe on adults undergoing aortic surgery (NCT0064798). The study was terminated prematurely because of the Food and Drug Administration (FDA) hold placed on the ESA studies of neuroprotection following publication of increased mortality in the Epo recipients enrolled in the European multicenter study of adult stroke patients [51] , therefore only nine adults received 1 mg/kg Darbe immediately prior to surgery. An additional cohort of nine untreated adult patients was obtained for comparison. There were no differences in the primary outcome of death or neurologic impairment between Darbe recipients (1 of 9, 11%) and controls (3 of 9, 33%, P ¼ 0.58), although the small number of patients enrolled precluded appropriate statistical analyses. Patients with perioperative neurologic ischemia had significantly higher concentrations of S100b and glial fibrillary acidic protein (GFAP), CSF biomarkers, measured in samples obtained from lumbar drains. There were no differences in these biomarkers between the Darbe and control groups (S100b: 214 vs. 260 ng/ml, P ¼ 0.69; GFAP: 22 vs. 580 pg/ ml, P ¼ 0.45), although all point estimates favored Darbe treatment.
In another study impacted by the FDA hold, Andropoulos et al. [52 & ] completed a randomized trial of Epo administered to neonates undergoing complex cardiac surgery (NCT0013240). Infants with Dtransposition, hypoplastic left heart syndrome, or aortic arch reconstruction were randomized to one preoperative and two postoperative doses Epo or placebo. Initial dosing was 1000 units/kg for the first 33 infants, which was decreased to 500 units/kg for the last 26 infants. MRI and developmental assessments were performed.
There were no differences between groups in the MRI findings of brain injury, clinical events, or death. Developmental assessment at 12 months revealed no statistical differences in cognitive or language outcomes between Epo and placebo groups, although the study was not powered to detect a difference. No adverse effects of Epo were reported. The authors concluded that a larger prospective trial was required to determine the efficacy of Epo for neuroprotection in this population.
CONCLUSION
Clinical studies in preterm and term infants have shown ESAs to be well tolerated, and evidence of neuroprotection is growing. Preterm infants administered ESAs during their newborn intensive care unit stay show higher cognitive scores and a lower incidence of neurodevelopmental impairment. Studies of ESA administration in term infants with HIE being cooled for encephalopathy are ongoing. Developmental follow-up of those term infants is progressing. ESAs hold great promise in providing neuroprotection and improving neurodevelopmental outcomes of preterm neonates. We are confident that ongoing research will generate a definitive body of evidence that ESAs are neuroprotective in term infants.
